Literature DB >> 28361176

Electrophysiological assessment for early detection of retinal dysfunction in β-thalassemia major patients.

Maria Dettoraki1, Antonis Kattamis2, Ioannis Ladas1, Konstantinos Maragkos3, Chryssanthi Koutsandrea1, Klio Chatzistefanou1, Konstantinos Laios4, Dimitrios Brouzas1, Marilita M Moschos5.   

Abstract

PURPOSE: The purpose of this study was to assess the role of various diagnostic tests in early detection of retinal changes in β-thalassemia major patients.
METHODS: Thirty-eight visually asymptomatic β-thalassemia major patients receiving regular blood transfusions and iron-chelation therapy with deferoxamine (group A, n = 13), deferasirox (group B, n = 11) or deferoxamine with deferiprone (group C, n = 14) and fourteen age- and sex- matched healthy individuals were included in the study. All participants underwent ophthalmoscopy, full-field electroretinography (ERG), visual evoked potentials (VEP), multifocal electroretinography (mfERG), fundus autofluorescence (FAF) imaging and optical coherence tomography (OCT) scans.
RESULTS: Retinal pigment epithelium changes were present in two cases. Scotopic ERG demonstrated decreased a-wave amplitude in groups A, B and C (p = 0.03, p = 0.002 and p = 0.002, respectively) and decreased b-wave amplitude in groups B and C (p = 0.002 and p = 0.01, respectively) compared to controls. Photopic ERG showed delayed b-wave latency in groups A and C (p = 0.03 and p = 0.03, respectively) ERG maximal combined response and VEP response did not differ between groups. MfERG showed reduced retinal response density in ring 1 in groups A, B, C (p < 0.001, p < 0.001, p = 0.001, respectively) and ring 2 in group B (p = 0.02) and delayed latency in ring 5 in groups A and B (p = 0.04 and p = 0.04, respectively). Abnormal FAF images appeared in three cases and OCT abnormalities in one case, whereas no changes were observed in controls (p = 0.55 and p = 1.00, respectively).
CONCLUSIONS: Full-field ERG and mfERG are more sensitive tools for detecting early retinal changes in β-thalassemia patients compared with ophthalmoscopy, VEP, FAF imaging and OCT scans.

Entities:  

Keywords:  Beta thalassemia major; Chelation therapy; Electroretinography; Retinal toxicity

Mesh:

Year:  2017        PMID: 28361176     DOI: 10.1007/s00417-017-3650-9

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  27 in total

1.  Hepatic iron concentration and total body iron stores in thalassemia major.

Authors:  E Angelucci; G M Brittenham; C E McLaren; M Ripalti; D Baronciani; C Giardini; M Galimberti; P Polchi; G Lucarelli
Journal:  N Engl J Med       Date:  2000-08-03       Impact factor: 91.245

2.  Macular vitelliform lesion in desferrioxamine-related retinopathy.

Authors:  Mohamed A Genead; Gerald A Fishman; Anastasios Anastasakis; Martin Lindeman
Journal:  Doc Ophthalmol       Date:  2010-06-09       Impact factor: 2.379

3.  ISCEV standard for clinical visual evoked potentials (2009 update).

Authors:  J Vernon Odom; Michael Bach; Mitchell Brigell; Graham E Holder; Daphne L McCulloch; Alma Patrizia Tormene
Journal:  Doc Ophthalmol       Date:  2009-10-14       Impact factor: 2.379

Review 4.  ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition).

Authors:  Donald C Hood; Michael Bach; Mitchell Brigell; David Keating; Mineo Kondo; Jonathan S Lyons; Michael F Marmor; Daphne L McCulloch; Anja M Palmowski-Wolfe
Journal:  Doc Ophthalmol       Date:  2011-10-30       Impact factor: 2.379

5.  Ocular changes in patients undergoing long-term desferrioxamine treatment.

Authors:  G B Arden; B Wonke; C Kennedy; E R Huehns
Journal:  Br J Ophthalmol       Date:  1984-12       Impact factor: 4.638

6.  Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine.

Authors:  Francesco Viola; Giulio Barteselli; Laura Dell'arti; Diego Vezzola; Edoardo Villani; Chiara Mapelli; Laura Zanaboni; Maria D Cappellini; Roberto Ratiglia
Journal:  Ophthalmology       Date:  2012-04-04       Impact factor: 12.079

7.  ELECTRORETINOGRAPHIC AND VISUAL-EVOKED POTENTIAL CHANGES IN RELATION TO CHELATION MODALITY IN CHILDREN WITH THALASSEMIA.

Authors:  Amany Abd El-Shazly; Weam Mohamed Ebeid; Rania Serag Elkitkat; Marwa Reda Deghedy
Journal:  Retina       Date:  2017-06       Impact factor: 4.256

8.  [Tamoxifen retinopathy: a case series of clinical and functional data].

Authors:  C Ritter; A B Renner; J Wachtlin; N E Bechrakis; L Krause
Journal:  Ophthalmologe       Date:  2008-06       Impact factor: 1.059

9.  Desferrioxamine-related ocular toxicity: a case report.

Authors:  Sumu Simon; Paul A Athanasiov; Rajeev Jain; Grant Raymond; Jagjit S Gilhotra
Journal:  Indian J Ophthalmol       Date:  2012-07       Impact factor: 1.848

View more
  4 in total

Review 1.  Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies.

Authors:  Samira Heydarian; Reza Jafari; Kiumars Nowroozpoor Dailami; Hassan Hashemi; Ebrahim Jafarzadehpour; Mohsen Heirani; Abbasali Yekta; Monireh Mahjoob; Mehdi Khabazkhoob
Journal:  Int Ophthalmol       Date:  2019-10-10       Impact factor: 2.031

2.  Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature.

Authors:  Constantine D Georgakopoulos; Foteini Tsapardoni; Elli V Kostopoulou; Olga E Makri
Journal:  BMC Ophthalmol       Date:  2018-09-12       Impact factor: 2.209

Review 3.  Visual electrophysiology in the assessment of toxicity and deficiency states affecting the visual system.

Authors:  Emily K O'Neill; Richard Smith
Journal:  Eye (Lond)       Date:  2021-07-21       Impact factor: 3.775

4.  Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major.

Authors:  Raffaele Nuzzi; Giada Geronazzo; Federico Tridico; Alessia Nuzzi; Paolo Caselgrandi; Antonio Giulio Piga
Journal:  Clin Ophthalmol       Date:  2021-05-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.